Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Interchange of vaccine products, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; Pfizer/ BioNTech Dose number 1, Dose number 2/ Pfizer / Moderna Dose number 3/ BioNTech Dose number 4; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 32-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Nov2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 31 years for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 31Jan2022 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), on 13Jan2021 as dose 1, single (Batch/Lot number: unknown) and on 03Feb2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Anxiety" (unspecified if ongoing), notes: Asthma until early 20s. I am 32. Anxiety.; "Asthma" (unspecified if ongoing), notes: Asthma until early 20s. I am 32. Anxiety. The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 31Jan2022, outcome "not recovered", described as "Pfizer/ BioNTech Dose number 1, Dose number 2/ Pfizer / Moderna Dose number 3/ BioNTech Dose number 4"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 08Jul2023, outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (05Jul2023) Negative, notes: Negative PCR test 05Jul2023; (08Jul2023) Positive, notes: It is my first. Positive test 08Jul2023; (19Jul2023) Positive, notes: 19Jul2023: Symptoms return (runny nose, mild cough) Positive antigen test nasal swab. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical information: The patients current age is 32 years. The patient does not have any Known allergies.  Adverse event: Jul2023 First symptoms: Tuesday 4 or Wednesday 5. The patient does not remember. Negative PCR test 05Jul2023. The patient tested because her sister had symptoms but was testing negative with nasal antigen. She still never tested positive on nasal antigen. This is her 3rd time with COVID. It is the patient first. Positive test 08Jul2023. No tests were taken between these dates. Paxlovid started Sunday the 9th, no doses were missed. Anti-viral details: Product: COVID 19 Treatment, brand: Paxlovid, Treatment start date: 09Jul2023, Treatment stop date: 13Jul2023, indication: Treatment of COVID-19. 19Jul2023: Symptoms return (runny nose, mild cough) Positive antigen test nasal swab.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the available information, a possible contributory role of the suspect product cannot be completely excluded for the reported events 'vaccination failure' and 'Covid-19' due to a plausible temporal association. Interchange of vaccine products might have played a causal role in the reported events.